ALR TECHNOLOGIES RELEASES AN OPEN LETTER TO SHAREHOLDERS

SINGAPORE, Dec 21 (Bernama-GLOBE NEWSWIRE) -- ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today releases an open letter to shareholders from Chairman and Chief Executive Officer Sidney Chan. A copy of the letter is presented in this press release, the original can be found at https://alrt.com/investors/2021lettertoshareholders. Dear Fellow Shareholders, 2021 has been a transformative year for ALRT within which we have accomplished many important milestones. Most notable is the formation of the animal health division. As discussed below, the successful launch of the GluCurve Pet CGM (Continuous Glucose Monitor) should lead to revenue, earnings, and positive cashflows in the second half of 2022. We have discussed partnership opportunities on the GluCurve Pet CGM with various interested pharmaceutical companies and have selected our top candidate and are targeting to finalize a definitive agreement by May 2022. Additionally, we have brought on key additions to the ALR Technologies corporate team, and we have laid the groundwork to revolutionize diabetes care in human health. I am grateful for the support of our current shareholders, and the interest we have received from potential institutional investors, investment funds, and retail investors alike. Shareholders have asked how all the latest developments connect and fit into the company roadmap. So, I thought it prudent to discuss the following five topics to give a holistic overview of what we have accomplished, what we seek to accomplish in 2022, and why we have chosen this path to bring value to stakeholders.

1. Continuous Glucose Monitor

2. Human Health Initiative

3. Animal Health

4. Pharmaceutical Partnership

5. Corporate Strategy

Continuous Glucose Monitor

Our diabetes management solution was designed to solve the biggest problem in diabetes care: Clinical Inertia, the failure to advance therapy on a timely basis. Our competitors’ products are all dependent on patient self-management, which we believe to be a fundamental flaw. We have created the only diabetes management platform based on active patient management. Utilizing artificial intelligence (AI), the only FDA cleared Insulin Dose Adjustment for long and fast acting insulins, patent pending Predictive A1C, and many other unique features, we greatly reduce the time and effort needed from the care team, while improving the effectiveness of care for the patient and addressing clinical inertia. Clinical trials and pilot studies have shown a 1.2% reduction of A1C over 6 months. To put that in perspective, the CDC has said that a 1% reduction in A1C reduces microvascular complications from diabetes by 40%.

Essentially, we know our Diabetes Solution works well from the feedback and data we received from studies and trials. But while we believe we have the best-in-class platform, it is utilizing a Blood Glucose Meter (BGM) to collect data. BGMs and diabetes test strips are quickly becoming a thing of the past. The industry wants CGMs, which are the best-in-class hardware for checking blood sugar. The growing demand for CGMs has stifled our attempts to sell our system paired with BGMs to payers, despite the positive results we have documented. http://mrem.bernama.com/viewsm.php?idm=42014